Related Experiment Video

Updated: Dec 21, 2025

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

8.8K

The therapeutic potential of BRD4 in cardiovascular disease

Shigang Lin1, Lizhong Du2

  • 1Department of Neonatology, The Children's Hospital, Zhejiang University School of Medicine, Hangzhou, China.

Hypertension Research : Official Journal of the Japanese Society of Hypertension
|May 16, 2020
PubMed

Insights

Bromodomain-containing protein 4 (BRD4) is crucial in cardiovascular diseases, not just cancer. Targeting BRD4 with small molecule inhibitors offers new therapeutic strategies for conditions like pulmonary arterial hypertension and heart failure.

Area of Science:

  • Cardiovascular Biology
  • Molecular Oncology
  • Epigenetics

Background:

  • Bromodomain-containing protein 4 (BRD4), a BET family member, is recognized for its role in cancer via super enhancers and oncogene regulation.
  • Emerging evidence highlights BRD4's significant involvement in various cardiovascular diseases.

Purpose of the Study:

  • To elucidate the mechanisms of BRD4 in cardiovascular diseases.
  • To review BRD4's role in pulmonary arterial hypertension, heart failure, atherosclerosis, and hypertension.
  • To discuss BRD4 inhibitors as potential therapeutic agents for cardiovascular conditions.

Main Methods:

  • Literature review and synthesis of current research on BRD4 function in cardiovascular systems.
  • Analysis of molecular pathways regulated by BRD4 in cardiovascular disease pathogenesis.
  • Evaluation of preclinical and clinical data on BRD4 inhibitors for cardiovascular diseases.

Main Results:

  • BRD4 regulates key genes and epigenetic mechanisms implicated in cardiovascular pathologies.
  • Specific cardiovascular diseases, including pulmonary arterial hypertension, heart failure, atherosclerosis, and hypertension, demonstrate BRD4 involvement.
  • Small molecule BRD4 inhibitors show promise in preclinical models of cardiovascular disease.

Conclusions:

  • BRD4 is a critical mediator in cardiovascular disease development and progression.
  • Targeting BRD4 presents a promising novel therapeutic avenue for treating cardiovascular diseases.
  • Further research into BRD4 mechanisms and inhibitor efficacy is warranted for clinical translation.
Keywords:
AtherosclerosisBRD4Cardiovascular diseaseHeart failurePulmonary arterial hypertension

More Related Videos

Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System02:47

Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System

Published on: May 12, 2023

1.8K
Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B11:44

Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B

Published on: January 19, 2022

2.8K

Related Concept Videos

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.4K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
673
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.1K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
807
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
3.9K
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
1.4K